Armistice Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Armistice Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,827	Closed	-$932K	–	212
2025 Q1	$932K	Buy	+3,827	New	+$1.15M	0.01%	168
2021 Q3	–	Sell	-18,000	Closed	-$11.6M	–	140
2021 Q2	$11.6M	Sell	18,000 -20,000	-53%	-$12.2M	0.21%	85
2021 Q1	$21.7M	Buy	38,000 +5,000	+15%	+$2.96M	0.5%	52
2020 Q4	$19.2M	Buy	33,000 +13,000	+65%	+$7.4M	0.65%	46
2020 Q3	$10.3M	Buy	+20,000	New	+$10.1M	0.37%	64
2020 Q1	–	Sell	-20,000	Closed	-$7.4M	–	83
2019 Q4	$7.4M	Buy	+20,000	New	+$7.05M	0.43%	58

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

FPA

First Pacific Advisors El Segundo, California $8.09B AUM 21.95% 1-Year Est. Return

Armistice Capital's BIO Position: Q2 2025 in Review

Armistice Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 3,827 shares — an estimated $932K sold.

Armistice Capital first reported a position in BIO in Q4 2019 and held it in 6 quarters. The position peaked at $21.7M in Q1 2021. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

Armistice Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
Armistice Capital sold 3,827 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $932K.
Armistice Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and held it in 6 quarters.
Armistice Capital's Bio-Rad Laboratories Class A position peaked at $21.7M in Q1 2021.
384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.